Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHIT1 | Q13231 | 2/20 | 0.34 |
| ▸ | CHIA | Q9BZP6 | 2/20 | 0.34 |
| ▸ | CHI3L1 | P36222 | 1/20 | 0.34 |
| ▸ | CHI3L2 | Q15782 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9653111 | 0.84 | TAAR1 (0.44) | AOC3HTR2AHTR2CHTR2BKCNH2 | |
| SCHEMBL16497719 | 0.70 | TAAR1 (0.43) | AOC3HTR2AHTR2CHTR2BKCNH2 | |
| SCHEMBL2297307 | 0.70 | TSHR (0.49) | AOC3TAAR1 | |
| SCHEMBL13858441 | 0.68 | PIK3CD (0.31) | MEN1KMT2A | |
| SCHEMBL1546247 | 0.68 | — | — | |
| SCHEMBL1796186 | 0.68 | APLNR (0.44) | AOC3ALDH1A1TAAR1 | |
| SCHEMBL6982347 | 0.68 | PYCR1 (0.42) | ALDH1A1TAAR1MEN1KMT2A | |
| SCHEMBL102928 | 0.67 | TSHR (0.42) | AOC3ALDH1A1CNR2 | |
| Ammonia Solution, Strong SCHEMBL4465336 | 0.66 | TSHR (0.41) | AOC3ALDH1A1CNR2 | |
| SCHEMBL357647 | 0.66 | TAAR1 (0.50) | AOC3HTR2AHTR2BALDH1A1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6710064-B2 | FOR THERAPY OF INFLAMMATORY OR IMMUNE DISEASES | BRISTOL-MYERS SQUIBB CO. | 2004-03-23 | — | — | US | disclosed |
| US-20020143035-A1 | Hydantoin compounds useful as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143035-A1 | Hydantoin compounds useful as anti-inflammatory agents | HRH4, IL4I1, HRH2 | AOC3 790/4885HTR2A 1846/4885HTR2C 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.